Healthcare provider profile · identity verified

Byron Alan Velander, MD

Internal Medicine · GRAND FORKS, ND · NPI 1578501672

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	276	77
Atorvastatin Calcium	Atorvastatin Calcium	272	88
Amlodipine Besylate	Amlodipine Besylate	209	70
Lisinopril	Lisinopril	174	55
Omeprazole	Omeprazole	162	49
Metoprolol Succinate	Metoprolol Succinate	158	50
Losartan Potassium	Losartan Potassium	156	46
Furosemide	Furosemide	138	45
Eliquis	Apixaban	131	40
Rosuvastatin Calcium	Rosuvastatin Calcium	126	39
Metoprolol Tartrate	Metoprolol Tartrate	108	34
Metformin Hcl	Metformin Hcl	107	36
Pantoprazole Sodium	Pantoprazole Sodium	103	41
Januvia	Sitagliptin Phosphate	83	16
Gabapentin	Gabapentin	82	24
Pravastatin Sodium	Pravastatin Sodium	81	28
Escitalopram Oxalate	Escitalopram Oxalate	78	17
Duloxetine Hcl	Duloxetine Hcl	74	22
Potassium Chloride	Potassium Chloride	74	26
Albuterol Sulfate Hfa	Albuterol Sulfate	66	25
Spironolactone	Spironolactone	65	17
Ezetimibe	Ezetimibe	63	22
Tamsulosin Hcl	Tamsulosin Hcl	62	17
Allopurinol	Allopurinol	61	18
Hydrochlorothiazide	Hydrochlorothiazide	61	22
Fluoxetine Hcl	Fluoxetine Hcl	60	12
Jardiance	Empagliflozin	58	16
Montelukast Sodium	Montelukast Sodium	57	16
Meloxicam	Meloxicam	54	15
Trulicity	Dulaglutide	52	11
Glipizide Er	Glipizide	49	18
Metformin Hcl Er	Metformin Hcl	47	17
Trazodone Hcl	Trazodone Hcl	44	16
Dexlansoprazole Dr	Dexlansoprazole	43	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	42	15
Oxybutynin Chloride Er	Oxybutynin Chloride	42	suppressed
Sertraline Hcl	Sertraline Hcl	41	14
Carvedilol	Carvedilol	40	14
Paroxetine Hcl	Paroxetine Hcl	40	suppressed
Simvastatin	Simvastatin	38	11
Fluticasone Propionate	Fluticasone Propionate	37	14
Lamotrigine	Lamotrigine	35	suppressed
Warfarin Sodium	Warfarin Sodium	34	suppressed
Alprazolam	Alprazolam	33	12
Divalproex Sodium	Divalproex Sodium	33	suppressed
Famotidine	Famotidine	33	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	32	suppressed
Citalopram Hbr	Citalopram Hydrobromide	31	11
Propranolol Hcl	Propranolol Hcl	29	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	29	suppressed
Tramadol Hcl	Tramadol Hcl	28	12
Quetiapine Fumarate	Quetiapine Fumarate	27	suppressed
Breo Ellipta	Fluticasone/Vilanterol	26	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	26	12
Atenolol	Atenolol	25	suppressed
Clopidogrel	Clopidogrel Bisulfate	25	11
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	24	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	24	suppressed
Alendronate Sodium	Alendronate Sodium	23	suppressed
Bupropion Xl	Bupropion Hcl	23	suppressed
Lovastatin	Lovastatin	23	suppressed
Pregabalin	Pregabalin	23	suppressed
Olanzapine	Olanzapine	22	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	20	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	20	18
Isosorbide Mononitrate Er	Isosorbide Mononitrate	20	suppressed
Nitrofurantoin	Nitrofurantoin Macrocrystal	20	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	19	suppressed
Glipizide	Glipizide	19	suppressed
Mirtazapine	Mirtazapine	19	suppressed
Prednisone	Prednisone	19	16
Risperidone	Risperidone	19	suppressed
Bumetanide	Bumetanide	18	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	18	suppressed
Spiriva Respimat	Tiotropium Bromide	18	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	18	suppressed
Xarelto	Rivaroxaban	18	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Clonazepam	Clonazepam	17	suppressed
Diclofenac Sodium	Diclofenac Sodium	17	suppressed
Finasteride	Finasteride	17	suppressed
Ibuprofen	Ibuprofen	17	suppressed
Memantine Hcl	Memantine Hcl	17	suppressed
Colestipol Hcl	Colestipol Hcl	16	suppressed
Glimepiride	Glimepiride	16	suppressed
Hydralazine Hcl	Hydralazine Hcl	16	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	16	13
Ropinirole Hcl	Ropinirole Hcl	16	suppressed
Valsartan	Valsartan	16	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	15	suppressed
Lansoprazole	Lansoprazole	15	suppressed
Ozempic	Semaglutide	15	suppressed
Buspirone Hcl	Buspirone Hcl	14	suppressed
Carbamazepine Er	Carbamazepine	14	suppressed
Farxiga	Dapagliflozin Propanediol	14	suppressed
Levetiracetam	Levetiracetam	14	suppressed
Topiramate	Topiramate	14	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	14	suppressed
Ventolin Hfa	Albuterol Sulfate	14	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	13	suppressed
Solifenacin Succinate	Solifenacin Succinate	13	suppressed
Synthroid	Levothyroxine Sodium	13	suppressed
Acarbose	Acarbose	12	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	12	12
Digoxin	Digoxin	12	suppressed
Incruse Ellipta	Umeclidinium Bromide	12	suppressed
Oxycodone Hcl	Oxycodone Hcl	12	suppressed
Zonisamide	Zonisamide	12	suppressed
Amoxicillin	Amoxicillin	11	suppressed
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	11	suppressed
Nitroglycerin	Nitroglycerin	11	suppressed
Nystatin	Nystatin	11	suppressed
Ondansetron Odt	Ondansetron	11	suppressed
Oxycontin	Oxycodone Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error